A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.
Targeting specific populations of individuals with type 2 diabetes for intensive interventions to optimize their insulin use may result in better glycemic control than an untargeted approach, findings from the TARGIT-Diabetes trial suggest.
Hypoglycemia is common among people being treated for type 2 diabetes, particularly those using insulin or a sulfonylurea, but the risk for severe episodes is only elevated among insulin users, suggest results of a prospective UK study.
A patient-specific cognitive behavioral therapy and lifestyle counseling intervention can significantly improve psychological outcomes in type 2 diabetes patients with depression and/or regimen-related distress, say researchers.
Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.
Assigning people with type 2 diabetes to 3 months of focused care with a specialist diabetes nurse after an episode of severe hypoglycemia reduces their risk for mortality over the following few years, research shows.
Data from the TrialNet Pathway to Prevention study shows that monitoring high-risk relatives of people with type 1 diabetes markedly reduces the risk for those who develop the condition presenting with diabetic ketoacidosis.
The latest update from the UK’s National Health Service Diabetes Prevention Programme shows that persistence pays, and reveals weight loss and a reduction in glycated hemoglobin levels for people who have so far completed the intervention.
A behavioral intervention has lasting effects on physical activity levels, fitness, and vascular risk in people with type 2 diabetes, show the 3-year results of the randomized Italian Diabetes and Exercise Study 2.
Adding the glucagon-like peptide-1 analog semaglutide to an existing sodium-glucose cotransporter 2 inhibitor improves glycemic control and bodyweight in patients with poorly controlled type 2 diabetes, SUSTAIN 9 data show.
Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.